CPHI Online is the largest global marketplace in the pharma ingredients industry
Socosur Chem. is a
French consulting company and its core business is importation and distribution of Active Substances with successful track record of ANSM GDP inspections.
Our 3 activities are
- Importation and Distribution focused on Active Pharmaceutical Ingredients, especially in Antibiotics, Cardiology, Ophthalmic and Oncology therapeutic...
2015On CPHI since
1 - 24Employees
Products from Socosur (3)
Product BrinzolamideSocosur offers wide range of api's which includes brinzolamideCategory: Ophtalmology
Therapeutic class: Carbonic anhydrase inhibitors
Contact us for more information
Product Ciclosporine ASocosur offers wide range of api's which includes ciclosporine a. Category: ophtalmology. Therapeutic class: immunosupressant. Contact us for more information.
Product Epinastine HydrochlorideSocosur offers wide range of api's which includes epinastine hydrochloride. Category: ophtalmologyTherapeutic class: antihistamine decongestant
Contact us for more information.
Socosur Resources (1)
Whitepaper Implications of calculating the PDE as the exposure limit for the analysis of risks in shared installationsIn November 2014, the European Medicines Agency (EMA) published the Directive EMA/CHMP/ CVMP/SWP/169430/2012 on the establishment of exposure limits based on health criteria during the manufacture of diﬀerent drugs in shared installations.In January 2015, the European Commission also revised Chapters 3 and 5 of the EU GMP Guidelines, updating the sections on the prevention of cross-contamination.
These updates entered into force in March of the same year.
Further, Annex 15 of the EU GMP Guidelines (item 10.6) stipulates that "The residual contamination limits of the product must be based on a toxicological assessment".
The dates for implementation of the new EMA Guidelines were June 2015 for new products and December 2015 for existing products (with deferral of these deadlines for a year for veterinary products).
Up until then, the limit values of 10 ppm or1/1000 of the lowest clinical dose were used for cleaning validations. The use of conventional limits translated, on the one hand into excessively restrictive limits for low toxicity products, far exceeding the limits necessary to guarantee patient safety. And on the other hand, the conventional limits did not oﬀer enough protection for products considered to be highly toxic. Up until then, the categories with the highest risks concerned “certain hormones", "certain cytotoxic agents", etc., with no speciﬁc criteria.
Release of the EMA Directive implies determining exposure limits in accordance with toxicological criteria, and on the basis of characteristics inherent to each substance.The PDE (Permitted Daily Exposure) is calculated from pharmacological, toxicological and pharmacokinetic data and is similar to the ADE value (Acceptable Daily Exposure) described in the IPSE (International Society for Pharmaceutical Engineering) RiskMaPP.The two values represent the maximum daily dose of a substance that is not likely to cause adverse eﬀects in an individual who is exposed to this dose or to a lower dose, every day throughout their life. In order to facilitate the implementation of these new GMP regulations in the pharmaceutical industry, the Socosur team of toxicology experts launched a project to calculate PDE values for Active Pharmaceutical Ingredients ("API"), as external service provider in January 2015.With an experience that is unique in Europe as a result of having performed the toxicological assessment and preparation of 1200 PDE monographs, we conducted an in-depth meta-analysis of the data obtained.A classiﬁcation of PDE values was established, identifying 5 groups and allocating a danger level to each of them.
The results were analyzed against the ATC classiﬁcation (anatomical, therapeutic, chemical) therapeutic groups.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance